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A randomized trial had suggested that high doses of
erythropoiesis-stimulating agents (ESAs) might increase the
risk of cardiovascular outcomes in predialysis diabetic
patients. To evaluate this risk in diabetic patients receiving
dialysis, we used data from 35,593 elderly Medicare patients
on hemodialysis in the US Renal Data System of whom
19,034 were diabetic. A pooled logistic model was used to
estimate the monthly probability of mortality and a
composite cardiovascular end point. Inverse probability
weighting was used to adjust for measured time-dependent
confounding by indication, estimated separately for diabetic
and non-diabetic cohorts. The adjusted 9-month mortality
risk, significantly different between an ESA dose of 45,000
and 15,000U/week, was 13% among diabetics and 5%
among non-diabetics. In diabetic patients, the hazard ratio
(HR) for more than 40,000U/week was 1.32 for all-cause
mortality and 1.26 for a composite end point of death and
cardiovascular events compared with patients receiving
20,000 to 30,000U/week. The corresponding HRs in non-
diabetic patients were 1.06 and 1.10, respectively. A smaller
effect of dose was found in non-diabetic patients. Thus,
higher ESA doses, which are often necessary to achieve high
hemoglobin levels, are not beneficial, and possibly harmful,
to diabetic patients receiving dialysis. Our findings support a
Food and Drug Administration advisory recommending that
the lowest possible ESA dose be used to treat hemodialysis
patients.
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Chronic kidney disease (CKD) and end-stage renal disease
(ESRD) hemodialysis patients assigned to normal hematocrit
(Hct) targets receive high doses of erythropoiesis-stimulating
agents (ESAs; also referred to as epoetin, epoetin-a, or
darbepoetin). Randomized trials have shown increased
mortality1 or no beneficial clinical effects2 among those
assigned to normal Hct targets, and observational studies3,4
have found no survival benefits among hemodialysis patients
receiving high ESA doses.
Nearly half of all CKD and dialysis patients have comorbid
diabetes. Compared with CKD patients without diabetes, those
with diabetes generally receive higher ESA doses, attain lower
Hct levels,5–7 have a higher mortality rate, and experience more
cardiovascular events.8 A recent randomized trial (Trial to
Reduce Cardiovascular Events with Aranesp Therapy; TREAT)
was restricted to diabetic CKD predialysis patients9 and found
no cardiovascular or renal benefits and an increased risk for
stroke for those assigned to darbepoetin treatment targeting
hemoglobin levels 413 g/dl compared with those assigned
placebo treatment with rescue treatment with darbepoetin for
hemoglobin levels o9 g/dl. It is therefore possible that the
apparent lack of a beneficial effect for those targeted to higher
hemoglobins in all previous randomized controlled trials as
well as in observational studies could be due to the mixing of
diabetic and non-diabetic patients in their study groups.
Whether the adverse effects of targeting normal hemoglo-
bins is due to the hemoglobin level or other factors remains
controversial. To achieve higher hemoglobin levels, most
patients require higher ESA doses. The adverse effects of higher
hemoglobin targets might be due to the higher ESA doses,
particularly in patients who might be ESA hyporesponsive. In
fact, a recent post hoc analysis of the TREAT Study found that
patients who had poor initial hematopoietic response to
darbepoetin were at greater risk for cardiovascular adverse
events and death.10 The authors could not determine whether
the initial poor response identified a patient at greater risk or
whether the increased risk was attributable to the higher doses
of darbepoetin they received. We designed an observational
study to estimate the effect of ESA exposure (epoetin-a)
on mortality and cardiovascular outcomes among elderly
hemodialysis patients with and without diabetes.
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RESULTS
Figure 1 depicts the selection process for patients included in
the analysis. The analysis for the death-only outcome
included 35,593 patients, of whom 19,034 (53%) were
diabetic. During the follow-up period, 8238 (23%) of the
patients were censored and 7179 (20%) died. The analysis for
the composite outcome included 32,534 patients (after 3059
patients were excluded for having had a stroke, myocardial
infarction (MI), or congestive heart failure (CHF) during
the study baseline period), of whom 17,387 (53%) were
diabetic. A total of 6933 patients (21%) were censored; 8512
(26%) had a composite event including 4868 deaths (57%)
and 3644 (43%) cardiovascular events. Of the 3,644
cardiovascular hospitalization events, 2117 (24.7%) were
for CHF, 726 (8.5%) were for stroke, and 801 (9.5%) were for
an MI. The event rates for diabetics and non-diabetics were
similar for both mortality and composite outcomes (data not
shown).
Compared with non-diabetics, diabetics were younger,
more likely to be male and black, had a more severe
comorbidity burden (higher Charlson score) with almost
three times as many cardiovascular comorbidities, and had an
increased likelihood of being hospitalized and for longer
periods of time (Table 1). Although diabetic patients were
more likely to receive predialysis epoetin therapy, they
received similar amounts of epoetin during the baseline
period and achieved similar Hct levels at the end of baseline
when compared with non-diabetic patients.
Figure 2 shows the adjusted survival curves under three
hypothetical epoetin dose levels: 15,000, 30,000, and
45,000U/week throughout the entire follow-up period and
for each outcome separately (Figure 2a shows death-only and
Figure 2b shows the composite outcome). The survival
decreased with increasing doses. For the lowest epoetin doses
of 15,000U/week, the 9-month risk of death was 20% (28%
for composite endpoint) among diabetics and 24% (31%)
among non-diabetics.
The difference in mortality risk between 30,000 and
15,000U/week was 9% (95% confidence interval (CI): 7 and
11%) among diabetics and 5% (95% CI: 2 and 7%) among
non-diabetics (P-value for heterogeneity¼ 0.04). The differ-
ence in mortality risk between 45,000 and 15,000U/week
was 13% (95% CI: 10 and 16%) among diabetics compared
with 5% (95% CI: 2 and 9%) among non-diabetics
(P-value¼ 0.002).
Table 2 presents the estimated average hazard ratios (HRs)
for both mortality and the composite outcome. The estimates
were consistent with the findings from the survival curves.
Among both diabetics and non-diabetics, lower epoetin dose
levels (o20,000U/week) were associated with lower risk for
both mortality and composite outcomes. In diabetic patients,
the HR (95% CI) for440,000U/week was 1.32 (1.11, 1.58) for
all-cause mortality and 1.26 (1.07, 1.50) for the composite end
point of death and cardiovascular events compared with a dose
of 20,000–30,000U/week. The corresponding HRs (95% CI) in
non-diabetic patients were 1.06 (0.88 and 1.28) and 1.10 (0.92
79,349 Elderly patients initiated hemodialysis within 90 days of the first ESRD service date in 2004 and 2005
65,091 Patients started epoetin treatment in the same month as hemodialysis
58,355 Patients received hemodialysis from non-hospital freestanding dialysis facilities (in contrast to hospital-based facilities)
56,528 Patients had Medicare as their primary payor
49,918 Patients used hemodialysis only during baseline and did not have a pre-ESRD diagnosis of cancer or HIV
Final death-only cohort 
35,593 Patients survived baseline period and had complete baseline variable information
19,034 Patients had
diabetes as primary ESRD
diagnosis and/or a
comorbid condition
(diabetic death cohort) 
16,559 Patients had
primary ESRD diagnosis
other than diabetes and no
comorbid diabetes
(non-diabetic death cohort) 
Final (CE) cohort 
32,534 Patients (3,289 excluded because of MI, stroke, CHF during baseline)
17,387 Patients had 
diabetes as primary ESRD
diagnosis and/or a 
comorbid condition
(diabetic CE cohort)  
15,147 Patients had primary
ESRD diagnosis other
than diabetes and no
comorbid diabetes
(non-diabetic CE cohort)
Figure 1 | Selection of study population from USRDS data. CE, composite end point; CHF, congestive heart failure; ESRD, end-stage renal
disease; MI, myocardial infarction; USRDS, United States Renal Data System.
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and 1.32), respectively. Results for HRs estimated using the first
dose level (o10,000U/week) as the reference group are shown
in the Supplementary Appendix Table S3 online.
In secondary analyses, the estimates were similar when we
made different assumptions about the amount of epoetin
used during hospitalizations (Supplementary Appendix
Figure S1 online). Our estimates did not materially change
when we used other summaries of epoetin use (that is, total
cumulative dosage from start of follow-up, recent, and past
cumulative average dosage) in the logistic model, cubic
splines with knots at different locations, inverse probability
(IP) weights that were not truncated (Supplementary
Appendix Table S2 online), IP weights estimated under a
gamma distribution for the log of epoetin dosage, alternative
categorizations of Hct values, expanded billable service (or
claims) gap definition from 30 to 60 days, censoring that did
not include change of provider, and censoring criteria that
included reduced dialysis sessions.
DISCUSSION
Our findings suggest that high ESA doses are associated with
a greater risk of death and cardiovascular outcomes. In
diabetic patients, the adjusted 9-month risk of death
increased from 20% for a dose of 15,000U/week to 33%
for 45,000U/week. The corresponding increase in non-
diabetic patients was smaller (from 24 to 30%).
Four randomized trials—CREATE, 2 CHOIR, 1 NHT,11
and TREAT10—had previously found no survival or
cardiovascular benefits among those targeted to higher Hcts
and therefore exposed to higher ESA doses. In contrast to our
findings, a post hoc analysis of the CHOIR Trial12 found that
non-diabetic, but not diabetic, CKD patients assigned to the
higher target group (who received higher doses on average)
had an increased risk of 70%. This finding, however, is hard
to interpret because in the CHOIR Trial diabetics and non-
diabetics assigned to low hemoglobin targets had similar
event rates, and non-diabetics had higher event rates than
diabetics assigned to the high hemoglobin target. Finding
similar or higher event rates in non-diabetics than diabetics is
somewhat surprising and might reflect unique features of
their study population or random variability. The authors of
the CHOIR secondary analysis reported that the relationship
between epoetin dose and outcomes could not be assessed in
diabetics because of small sample size.
Table 1 | Characteristics of study population (N=35,593)
Diabetics Non-diabetics
N 19,034 15,559
Patient demographics
Race (%)
White 67.9 74.7
Black 26.1 21.1
Other/unknown 6.0 4.2
Mean age (years) 74.1 77.2
Male sex (%) 53.1 46.9
Facility characteristics
Region
Northeast (networks 1–5) 23.8 26.2
Southeast (networks 6–8, 13, 14) 35.8 33.1
Midwest (networks 9–12) 23.5 24.6
West (networks 15–18) 16.9 16.1
Chain membership (%)
Chain 1 32.4 31.1
Chain 2 14.1 14.1
Chain 3 16.9 17.1
Chain 4 9.9 10.4
Chain 5 3.9 4.0
Chain 6 1.0 1.0
Small chain/non-chain 21.8 22.4
Patient clinical history
Cause of ESRD (%)
Diabetes 86.3 NA
Hypertension 9.7 66.5
Glomerulonephritis 1.1 9.0
Cystic kidney 0.1 2.1
Other 2.9 22.5
Body weight (Kg)
o61 16.7 29.9
61 to o72 22.9 27.6
72 to 84 25.3 23.5
X84 35.2 19.0
Charlson index scorea
o3 6.6 30.3
3 to o6 27.5 29.3
6 to o8 26.0 15.2
X8 39.9 25.2
Hospitalization (days)a
0 56.7 57.7
o5 11.3 11.8
5 to o10 12.5 12.2
X10 19.5 18.3
Cardiovascular comorbidities (%) 49.1 34.8
Non-cardiovascular comorbidities (%) 67.6 11.4
Anemia management practices
Receipt of predialysis epoetin (%) 36.7 33.7
Hematocrit level at end of month 3 (%)
o30% 5.1 5.3
30 to o33% 9.0 8.9
33 to o36% 19.1 19.4
36 to o39% 27.0 26.9
X39% 39.8 39.4
Epoetin dose (U/week)a
o10,000 9.2 9.8
10,000 to o20,000 29.6 30.2
20,000 to o30,000 29.3 28.4
30,000 to o40,000 16.8 16.3
X40,000 15.1 15.3
Table 1 | Continued
Diabetics Non-diabetics
Average iron (U/month)a
o450 18.1 20.2
450 to o800 19.7 19.6
800 to o1,200 26.8 26.5
X1,200 35.4 33.6
Abbreviation: ESRD, end-stage renal disease.
aFirst 3 months of dialysis therapy.
Note: Diabetics defined as patients with diabetes as primary cause of ESRD. Non-
diabetics defined as other primary cause of ESRD.
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Our results support a harmful effect of receiving high
epoetin doses, which might explain the higher risk found in
the TREAT Trial among patients who were initially
hyporesponsive to ESA therapy and who subsequently
received the higher doses of darbepoetin-a and were at
highest risk for adverse outcomes.10 There are several
pathways through which higher epoetin exposures could be
detrimental, including an increased risk of hypertension and
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Figure 2 |Adjusted survival curves. (a) Survival probabilities for three selected epoetin dosage regimens: low dosage (15,000U/week),
medium dosage (30,000U/week), and high dosage (45,000 U/week). (b) Composite outcome defined as death or hospitalization for
myocardial infarction, stroke, or congestive heart failure. CI, confidence interval; RD, risk difference; ref., reference.
Table 2 | Cumulative average epoetin dose and HRs based on IP weighting
Death only Compositea
Epoetin dose
Diabetic Non-diabetic Diabetic Non-diabetic
U/week HR 95% CI HR 95% CI HR 95% CI HR 95% CI
o10,000 0.69 0.57 0.83 0.71 0.57 0.88 0.80 0.67 0.94 0.69 0.57 0.82
10,000 to o20,000 0.70 0.60 0.81 0.86 0.72 1.02 0.86 0.75 0.99 0.89 0.76 1.04
20,000 to o30,000 (reference group) Ref. Ref. Ref. Ref.
30,000 to o40,000 1.21 0.98 1.51 1.12 0.91 1.38 1.21 1.00 1.47 1.14 0.94 1.39
X40,000 1.32 1.11 1.58 1.06 0.88 1.28 1.26 1.07 1.50 1.10 0.92 1.32
Abbreviations: CHF, congestive heart failure; CI, confidence interval; HR, hazard ratio, IP, inverse probability; MI, myocardial infarction; ref., reference.
aComposite outcome is death or hospitalization for MI, stroke, or CHF.
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thrombosis. According to Vaziri et al.13 and others,14,15
chronic erythropoietin administration results in a Hct-
independent, elevated vasoconstriction-dependent hypertension.
Observational studies have shown that diabetes is asso-
ciated with increased mortality in anemic CKD patients6 and
that anemia is associated with an increased risk of
cardiovascular events in CKD patients with diabetes.6,7
At high ESA levels, diabetic hemodialysis patients could be
at a higher risk for adverse outcomes when compared with
their non-diabetic counterparts due to the increased presence
of hypertension in this group.16 Extra-hematopoietic effects of
epoetin use, particularly worsening of hypertension, should be
explored to determine whether it contributes to an increase in
mortality and cardiovascular events among hemodialysis
diabetic patients who are exposed to high ESA doses.
Residual confounding might also partly explain our
findings. Similar to previous observational studies,17–20 ours
found a strong association between dose and mortality when
not adjusting for the measured confounders or when using
standard adjustment methods (Supplementary Appendix
Table S1 online). Confounding adjustment via IP weight-
ing—a theoretically correct method—brought the HRs closer
to the null. A similar trend was reported in other
observational studies that adjusted for confounding via IP
weighting19,21 or instrumental variable estimation.17 It is
possible that further adjustment for factors that were
unavailable (for example, use of insulin, b-blockers, and
other drugs) could further attenuate the estimated risk at
elevated dose levels. Interestingly, none of the published
observational studies found a lower risk among those
receiving higher epoetin doses.
Our analysis has several limitations. First, the diagnosis of
diabetes might be underreported in the United States Renal
Data System (USRDS), and thus the differences we found
between diabetics and non-diabetics might be attenuated.
Second, the diagnosis of cardiovascular disease might also be
imperfect because Medicare claims data were collected
primarily for the purposes of billing for healthcare services.
To limit the number of false positives for cardiovascular
disease (which were identified by using International
Classification of Disease, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) codes in our study), we used only the
primary reason (diagnosis) for hospitalization, that is, CHF,
or MI, or stroke. Third, use of iron might be overstated
because of Medicare billing peculiarities dictating that
providers’ bill for iron in vial size amounts (for example,
100mg/vial) as opposed to billing for the actual amount
administered to the patient.
In conclusion, our findings suggest that using higher ESA
doses as would be needed to achieve higher hemoglobin
levels is not beneficial, and is possibly harmful, for diabetic
patients. A smaller effect of dose was found in non-diabetic
patients. Our results are consistent with Food and Drug
Administration’s (FDA’s) recent advisories that recommend
the lowest possible ESA dose be used when treating
hemodialysis patients.
MATERIALS AND METHODS
Study data
The USRDS is the national source for demographic and clinical data
regarding ESRD patients and their institutional providers of dialysis
treatment. Medicare coverage is provided for 93% of US dialysis
patients. The USRDS Medicare claims database includes the
monthly Hct and epoetin dose administered to Medicare dialysis
patients. The ‘Researcher’s Guide to the USRDS Database’, available
from http://www.usrds.org, describes variables, data sources, collec-
tion methods, and validation studies. We merged the USRDS
standard analytic files for the calendar years 2004–2006 with the
USRDS core CD files that contained variables from patient, medical
evidence, facility, and physician/supplier data files.
We identified incident hemodialysis patients who were 65 years
and older, received their first ESRD service between 2004 and 2005,
received their first outpatient dialysis service within the first 90 days
after being certified as ESRD, did not have missing claims data
during the 90-day baseline period, and had Medicare as their
primary payer. These inclusions ensure that we had the complete
Medicare (parts A and B) claims treatment history for our study
group. Patients treated in hospital-based dialysis facilities have more
comorbidities and a higher mortality rate when compared with
those treated in freestanding dialysis facilities;22 hence, we
restricted our study population to patients treated in freestanding
facilities. We also excluded patients with a history of HIV or cancer
as these patients might respond differently to epoetin therapy
compared with the ESRD population at large.23–25 Patients who
received darbepoetin (0.9%) were excluded from the study. Finally,
we classified a patient as diabetic if diabetes was reported to be the
primary cause of renal failure and/or diabetes was listed as a
comorbid condition on the Medical Evidence Form 2728, which is
completed when a patient enrolls in the Medicare ESRD program
(Figure 1).
Outcome ascertainment
The two end points of interest were all-cause mortality and a
composite outcome including death and hospitalization for MI,
stroke, or CHF. The composite outcome was similar to the one used
in two recent ESA randomized trials.1,9 We defined the cardiovas-
cular events included in the composite outcome measure by using
the following ICD-9-CM codes: MI: codes 410.xx (except 410.x2);
CHF: codes 402.x1, 425.xx, 428.xx, 518.4, and 398.91; and stroke:
codes 430.xx, 431.xx, 432.xx, 433.xx, and 434.xx. Using these ICD-9
codes found on Medicare hospital claims, we determined the
primary reason for hospitalization and identified those patients who
experienced an event of interest.
Definition of follow-up and treatment
Once the initial 3 months of outpatient dialysis treatment had
passed, patient follow-up began. The observation period ended 9
months later, or at death, or at a censoring event, whichever
happened the earliest. The censoring events included: a change of
dialysis modality; receipt of a kidney transplant; at 60 days after
change of dialysis provider, or when a 30-day gap in outpatient
dialysis services occurred. Patients who had experienced any of these
censoring events during the first 3 months on dialysis were also
excluded from the analysis.
For each patient and each month of follow-up, we calculated the
cumulative average dose of epoetin as the cumulative dose received
since the start of follow-up divided by the time of follow-up.
Epoetin administered during hospitalization is not available on
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Medicare claims data, although it is likely that hemodialysis patients
with longer hospital stays would have received some epoetin. As in
our previous study,4 we assumed that patients receive epoetin from
day 5 of hospitalization onward at the same dose level (dose per
administration) as they received during their immediate pre-
hospitalization outpatient dialysis period. We also conducted a
sensitivity analysis where we assumed that the same pre-hospitaliza-
tion epoetin dose was given throughout the hospital stay.
Statistical methods
We fit a pooled logistic model to estimate the monthly probability of
the outcome as a function of cumulative average log epoetin dose
(cubic splines with knots located at 5th, 25th, 75th, and 95th
percentiles of dose before that month), baseline covariates measured
at the start of the follow-up, and cubic splines of follow-up (months).
Our model also included product (‘interaction’) terms between
cumulative average log epoetin dose and the month variables.
As higher epoetin doses are more likely to be prescribed to
patients with lower Hcts who also might be at higher mortality and
cardiovascular risk, the estimates from our model needed to be
adjusted for the effect of time-dependent confounding by indica-
tion.26 As previously described,27 we used IP weighting to adjust for
time-dependent confounding by measured time-varying covariates,
including Hct, iron treatment, and hospitalization. When the
outcome of interest was death only, we also adjusted the model
for hospitalization due to CHF, MI, and stroke.
Each patient received a time-varying weight inversely propor-
tional to the estimated probability of having his/her own observed
epoetin dose history, as described elsewhere.4 Briefly, the IP weights
were estimated by fitting two nested models: (1) a logistic regression
model to estimate each patient’s probability of not receiving epoetin
at any given month (7% of the patient-months had zero dose) and
(2) a linear regression model to estimate each patient’s density
(assumed to be normal) of the log epoetin dose among those
patients with non-zero dose in that month. Both models included
the baseline covariates and time-varying covariates listed above plus
the following product terms: between Hct and log epoetin dose;
between Hct and hospitalization; and between chains and both
baseline epoetin dose and time-varying epoetin dose (because chain
characteristics are associated with epoetin dosing patterns28). IP
weights were also estimated to adjust for potential selection bias
because of censoring. Both the epoetin dose and censoring weights
were stabilized and the product (of these weights) was used to fit the
weighted regression model. The mean of estimated epoetin
treatment weights was 1.02, and the 99th percentile was 5.80. The
mean of the estimated censoring weights was 0.99, and the 99th
percentile was 1.07. We truncated the IP weights to a maximum of
20 and used those observations in the primary analyses. Truncation
did not materially affect the point estimates. All models were fit
separately for diabetic and non-diabetic patients.
We then applied the weighted logistic model to estimate the
survival curve under three hypothetical scenarios: all patients exposed
to a cumulative average dose of (1) 15,000U/week, (2) 30,000U/week,
and (3) 45,000 /week. These dose levels were selected to approximate
low, average, and high exposure to epoetin. Point-wise 95%
confidence intervals for the survival model were calculated via
percentile-based non-parametric bootstrap based on 200 full samples.
For comparison with previous analyses, we also estimated
average HRs over the entire follow-up. We fitted the weighted
logistic model for this outcome without product terms between
epoetin dose and other variables, and with epoetin dose replaced by
a categorical variable at five dose levels: 0 to o10,000; 10,000 to
o20,000; 20,000 to o30,000; 30,000 to o40,000; and X40,000
U/week. The reference group, chosen to represent FDA-recommended
dosage levels, was 20,000–30,000U/week. To assess potential effect
modification by diabetic status, we estimated the 9-month survivals
separately in diabetics and non-diabetics and used bootstrapping
(200 samples) to test whether the differences were equal to zero. All
analyses were conducted with SAS 9.1 (SAS Institute, Cary, NC).
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regimens: Low dosage (15,000 U/week), medium dosage (30,000
U/week), and high dosage (45,000 U/week), based on the secondary
analysis which inputs epoetin throughout the duration of the
hospital stay. (B) Composite outcome defined as death or
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failure.
Table S1. Cumulative average epoetin dose and hazard ratios (HR)
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